Results 181 to 190 of about 44,321 (338)

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia A in paediatric patients presents a lifelong risk of spontaneous and trauma‐induced haemorrhage, leading to progressive joint damage, disability and impaired quality of life. Emicizumab, a bispecific monoclonal antibody administered subcutaneously, offers sustained haemostatic protection and has shown promising ...
Konstantina Bolou, George Triantafyllou, Athina Dettoraki, Aikaterini Michalopoulou, Miltiades Kyprianou, Olympia Papakonstantinou, Helen Pergantou   +6 more
wiley   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

Haemophilia, EarlyView.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen, Anthony K. C. Chan, Davide Matino, Emma Iserman, Arun Keepanasseril, Karen Strike   +5 more
wiley   +1 more source

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies [PDF]

, 2017
Arber, Caroline, Bonifant, Challice Lee, Cooper, Laurence J. N., Gerken, Claudia, Gottschalk, Stephen, Iwahori, Kota, Kakarla, Sunitha, Rodriguez-Cruz, Tania, Song, Xiao-Tong, Szöőr, Árpád, Torres, David, Velasquez, Mireya Paulina   +11 more
core   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy. [PDF]

Mol Cancer
Battistini E, Lapuhs P, Jiménez A, Garrido-Areal S, Rivas-Gómez L, Zagorac I, Álvarez-Vallina L, Alonso MJ, Sanjurjo L.   +8 more
europepmc   +1 more source

Acute lymphoblastic B‐cell leukemia or CAR‐T cell related skin changes – a relevant diagnostic challenge

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Farzan Solimani, Amrei Dilling, Konrad Heisterkamp, Frederik Damm, Olaf Penack, Christian Oberender, Philipp Le‐Coutre, Martina Rudelius, Kamran Ghoreschi, Alexander Nast   +9 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Advances in the clinical application of bispecific antibodies in cancer therapy. [PDF]

iScience
Zhou S, Li F, Niu M, Wu K, Li T, Yi M.
europepmc   +1 more source